Strategic collaborations Alamar is actively pursuing national-scale research collaborations with major universities (Washington University in St. Louis, University of Wisconsin, Indiana University) to generate large multiplexed plasma proteomic datasets for Alzheimer's disease and related dementias, presenting a clear entry point for joint grant-funded or funded research opportunities and potential upsell of NULISAseq Neuro 220 panels.

Expanded diagnostic roadmap The company is developing a diagnostic version of its ARGO HT/DX platform for FDA submission in 2027, signaling a shift from research-use tools to clinically deployable solutions, which opens cross-sell potential to hospitals, CLIA labs, and diagnostics focused CROs.

Productization momentum Recent launches such as the commercial eMTBR-Tau immunoassay within the NULISAseq Neuro 220 panel and the automated, low hands-on-time workflow on ARGO systems position Alamar to upsell to existing instrument users and broaden adoption among proteomics labs seeking automated, high-throughput capabilities.

Financial traction Strong revenue growth with quarterly top-line expansion and a recent IPO funding round underpin credibility and budget availability in potential accounts, suggesting readiness for larger multi-site deployments, maintenance contracts, and consumables replenishment.

Market leadership With a unique NULISA chemistry delivering high sensitivity and dynamic range across multiplex panels and readouts (qPCR and NGS), Alamar can position as a premium supplier to mid-to-large biotech and academic labs pursuing ambitious proteomics programs, enabling value-based deals and strategic partnerships.